Jobs / United States / Astrazeneca Pharmaceuticals Lp
Clinical Trial Engagement Lead (12-month contract)
Astrazeneca Pharmaceuticals Lp · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Senior Director, External Expert Engagement Services” (Computer and Information Systems Managers) in DE: $215k–$215k, median $215k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Note** This is a 12-month contract At AstraZeneca, we pride ourselves on crafting a collaborative culture that champions knowledge-sharing, ambitious thinking and innovation – ultimately providing employees with the opportunity to work across teams, functions and even the globe. Recognizing the importance of individualized flexibility, our ways of working allow employees to balance personal and work commitments while ensuring we continue to create a strong culture of collaboration and teamwork by engaging face-to-face in our offices 3 days a week. Our head office and in downtown Toronto are purposely designed with collaboration in mind, providing space where teams can come together to strategize, brainstorm and connect on key projects. Our dedication to sustainability is also central to our culture and part of what makes AstraZeneca a great place to work. We know the health of people, the planet and our business are interconnected which is why we’re taking ambitious action to tackle some of the biggest challenges of our time, from climate change to access to healthcare and disease prevention. The Clinical Trial Engagement Lead – Oncology drives a best-in-class site relationship model to position AstraZeneca as the Sponsor of Choice for clinical sites. This role builds and sustains strategic, long-term relationships with key Oncology institutions, including deep engagement with Key External Experts (KEEs) and operational leaders (investigators, site managers, study coordinators, regulatory, pharmacy etc.) to align on trial needs, remove barriers, and elevate the site experience. Acting as the primary interface for clinical trials, the role enhances AZ’s local reputation and optimizes clinical trial environments for timely, high-quality delivery. Key accountabilities include implementing local site relationship strategies (including Partner in Care Network where applicable), monitor and support study start-up on-time enrolment and database flow for the sites they have been assigned and escalate findings from vendor monitoring activities . The role collaborates across clinical, legal, contracts, vendors, and other functions. Accountabilities: • End-to-end site delivery: Ensure comprehensive site management to achieve enrollment readiness, recruitment goals, and timely locks, including performance management, issue mitigation, and resolution. • Maximize enrollment and experience: Identify and implement opportunities to maximize enrollment timelines while delivering an unparalleled clinical trial and customer experience for investigators, site staff, and patients. • Scientific and regional insight: Apply provided scientific, therapeutic area information, and institutional/regional knowledge to inform feasibility, strategic site allocation, and delivery of high-quality data; understand the provided AZ oncology tumour strategy map and how ongoing/planned AZ studies complement evolving treatment strategies to maximize patient benefit, align with site priorities, and support timely enrolment. • Strategic relationships and networks: Build and expand strategic institutional/site partnerships across academic centers, community practices, and emerging models (hybrid networks, DCT-enabled sites); engage KEEs, investigators, research coordinators, and site leadership to optimize trial delivery across therapeutic areas where applicable. • Data-driven decisions: Leverage site/country/regional metrics and KPIs (quality and performance) to guide decisions, track compliance with partnership agreements, diagnose issues, and drive corrective actions. • Barrier removal and issue escalation: Collaborate with internal teams to remove execution barriers at site and country levels; serve as an escalation point for site performance issues and impl